Dishman Carbogen Amcis
Market Cap
₹25.8b
Last Updated
2019/10/15 12:54 UTC
Data Sources
Company Financials +
Executive Summary
Dishman Carbogen Amcis Limited provides contract research and manufacturing services worldwide.
Snowflake
Fundamentals
Flawless balance sheet and undervalued.
Similar Companies
Share Price & News
How has Dishman Carbogen Amcis's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
0.3%
540701
3.4%
IN Life Sciences
2.3%
IN Market
1 Year Return
-32.6%
540701
18.7%
IN Life Sciences
0.3%
IN Market
Return vs Industry: 540701 underperformed the Indian Life Sciences industry which returned 18.7% over the past year.
Return vs Market: 540701 underperformed the Indian Market which returned 0.3% over the past year.
Shareholder returns
| 540701 | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.3% | 3.4% | 2.3% |
| 30 Day | -11.8% | 2.6% | 2.2% |
| 90 Day | -24.8% | 0.3% | -2.7% |
| 1 Year | -32.6%-32.6% | 19.6%18.7% | 2.3%0.3% |
| 3 Year | n/a | 33.6%30.5% | 20.7%14.7% |
| 5 Year | n/a | 127.8%120.2% | 41.4%28.2% |
Price Volatility Vs. Market
How volatile is Dishman Carbogen Amcis's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Dishman Carbogen Amcis undervalued compared to its fair value and its price relative to the market?
28.3%
Undervalued compared to fair value
Share Price vs. Fair Value
Undervalued: 540701 (₹160.8) is trading below our estimate of fair value (₹224.34)
Significantly Undervalued: 540701 is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: 540701 is good value based on its PE Ratio (12.7x) compared to the Life Sciences industry average (23.7x).
PE vs Market: 540701 is good value based on its PE Ratio (12.7x) compared to the Indian market (13.1x).
Price to Earnings Growth Ratio
Low PEG Ratio: 540701 is good value based on its PEG Ratio (0.5x)
Price to Book Ratio
PB vs Industry: 540701 is good value based on its PB Ratio (0.5x) compared to the IN Life Sciences industry average (1.4x).
Next Steps
Future Growth
How is Dishman Carbogen Amcis forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
26.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 540701's forecast earnings growth (26.5% per year) is above the savings rate (7.6%).
Earnings vs Market: 540701's earnings (26.5% per year) are forecast to grow faster than the Indian market (18.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 540701's revenue (11.2% per year) is forecast to grow slower than the Indian market (11.4% per year).
High Growth Revenue: 540701's revenue (11.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: Insufficient data to determine if 540701's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Dishman Carbogen Amcis performed over the past 5 years?
38.9%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: 540701 has become profitable over the past 5 years, growing earnings by 38.9% per year.
Accelerating Growth: 540701's earnings growth over the past year (13.1%) is below its 5-year average (38.9% per year).
Earnings vs Industry: 540701 earnings growth over the past year (13.1%) exceeded the Life Sciences industry 11.1%.
Return on Equity
High ROE: 540701's Return on Equity (3.8%) is considered low.
Return on Assets
ROA vs Industry: 540701's Return on Assets is below or equal to the Life Sciences industry average last year.
Return on Capital Employed
ROCE Improving: 540701's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is Dishman Carbogen Amcis's financial position?
Financial Position Analysis
Short Term Liabilities: 540701's short term assets (₹15.5B) exceeds its short term liabilities (₹12.0B)
Long Term Liabilities: 540701's short term assets (15.5B) exceeds its long term liabilities (7.5B)
Debt to Equity History and Analysis
Debt Level: 540701's debt to equity ratio (15.4%) is considered satisfactory
Reducing Debt: 540701 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: 540701's debt is well covered by operating cash flow (34%).
Interest Coverage: 540701's interest payments on its debt are well covered by EBIT (5.3x coverage).
Balance Sheet
Inventory Level: 540701 has a high level of physical assets or inventory.
Debt Coverage by Assets: 540701's debt is covered by short term assets (assets are 1.875180x debt).
Next Steps
Dividend
What is Dishman Carbogen Amcis's current dividend yield, its reliability and sustainability?
0.12%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: 540701's dividend (0.12%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.6%).
High Dividend: 540701's dividend (0.12%) is low compared to the top 25% of dividend payers in the Indian market (2.5%).
Stable Dividend: 540701 is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.
Growing Dividend: 540701 is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: 540701 is not paying a notable dividend for .
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 540701's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.
Next Steps
Management
What is the CEO of Dishman Carbogen Amcis's salary, the management and board of directors tenure and is there insider trading?
2.6yrs
Average board tenure
CEO
Arpit Vyas (33yo)
0yrs
Tenure
₹12,000,000
Compensation
Mr. Arpit Janmejay Vyas has been Group Managing Director of Dishman Carbogen Amcis Limited since November 28, 2018 and as its Director since April 7, 2012. He served as Chief Financial Officer and Managing ...
CEO Compensation Analysis
Compensation vs. Market: Insufficient data to establish whether Arpit's total compensation is reasonable compared to companies of similar size in the Indian market.
Compensation vs Earnings: Arpit's compensation has been consistent with company performance over the past year.
Board Age and Tenure
2.6yrs
Average Tenure
66yo
Average Age
Experienced Board: 540701's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Management Team
Mark Griffiths (55yo)
Director of Global Marketing & Strategy and Director
- Tenure: 2.6yrs
Alan Fischer
Global Chief Information Officer
- Tenure: 0yrs
Deohooti Vyas (68yo)
Whole Time Director
- Tenure: 2.6yrs
- Compensation: ₹12.00m
Janmejay Vyas (68yo)
Chairman of the Board
- Tenure: 0yrs
- Compensation: ₹15.82m
Arpit Vyas (33yo)
Group MD & Director
- Tenure: 0yrs
- Compensation: ₹12.00m
Stephan Fritschi
Vice President of Operations
- Tenure: 0yrs
Shrima Dave
Compliance Officer & Company Secretary
- Tenure: 0yrs
- Compensation: ₹698.00k
Harshil Dalal
Global Chief Financial Officer
- Tenure: 0.9yrs
- Compensation: ₹8.75m
Dharmesh Desai
GM of Secretarial & Legal
- Tenure: 0yrs
Dieter Thueer
Global Head of Human Resources
- Tenure: 0yrs
Board Members
Mark Griffiths (55yo)
Director of Global Marketing & Strategy and Director
- Tenure: 2.6yrs
Ashok Gandhi (80yo)
Independent Director
- Tenure: 2.6yrs
- Compensation: ₹1.48m
Deohooti Vyas (68yo)
Whole Time Director
- Tenure: 2.6yrs
- Compensation: ₹12.00m
Janmejay Vyas (68yo)
Chairman of the Board
- Tenure: 0yrs
- Compensation: ₹15.82m
Sanjay Majmudar (56yo)
Independent Director
- Tenure: 2.6yrs
- Compensation: ₹1.90m
Arpit Vyas (33yo)
Group MD & Director
- Tenure: 0yrs
- Compensation: ₹12.00m
Subir Das (66yo)
Independent Director
- Tenure: 2.6yrs
- Compensation: ₹1.33m
Rajendra Shah (71yo)
Independent Director
- Tenure: 2.6yrs
- Compensation: ₹920.00k
Maitri Mehta (37yo)
Independent Director
- Tenure: 0.5yrs
Company Information
Dishman Carbogen Amcis Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Dishman Carbogen Amcis Limited
- Ticker: 540701
- Exchange: BSE
- Founded: 2007
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹25.759b
- Shares outstanding: 161.39m
- Website: https://www.dishmangroup.com
Location
- Dishman Carbogen Amcis Limited
- Dishman Corporate House
- Opp. Jayantilal Park BRTS Bus Stop
- Ahmedabad
- Gujarat
- 380058
- India
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 540701 | BSE (Mumbai Stock Exchange) | Yes | Equity Shares | IN | INR | Sep 2017 |
| DCAL | NSEI (National Stock Exchange of India) | Yes | Equity Shares | IN | INR | Sep 2017 |
Biography
Dishman Carbogen Amcis Limited provides contract research and manufacturing services worldwide. It manufactures and supplies marketable molecules, such as bulk drugs, intermediates, quaternary ammonium com ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/15 12:54 |
| End of Day Share Price | 2019/10/15 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.